We invite you to read the most recent distribution of News You Can Use, which includes the prostate cancer articles listed below.
On October 1, Us TOO joined representatives from other prostate cancer organizations to participate in a conference call hosted by Bayer HealthCare to proactively inform the prostate cancer community about the temporary supply disruption of Xofigo® (radium Ra 223 dichloride). Xofigo was recently approved by the FDA as treatment for men with castrate resistant metastatic prostate cancer (CRPC) with bone metastases without any known visceral metastases. Production delays are not uncommon with radiopharmaceuticals. Xofigo received by anyone to date is safe and meets all quality standards. This is a fluid situation and we will continue to monitor it.